JPMA urges government to strengthen support for unapproved drugs to deliver essential medicines to patients
There are "drugs that are not yet available in Japan, but have been approved overseas. This is called "drug loss" and is a problem especially in the fields of pediatrics and rare diseases. The JPMA is requesting that the Japanese government provide more support for the efforts to make such drugs available in Japan, from the standpoint of companies. There is a system under which the government publicly solicits applications for drugs for which development companies cannot be found, but there is a lack of information and concerns about profitability for companies to take on these projects, and the hurdles are high in the field.
In this report, Chairperson Yuji Kashiwa⾕ of the Regulatory Affairs Committee, Yukiko Sakakibara, leader of the Industrial Policy Committee's Drug Lost Task Force, and other related committee members called for "more effective support measures that focus on the entire process from development to delivery to patients.
This article was published in Nikkan Yakugyo on July 15, 2025 [license number 20250715_02]. Jippo Co., Ltd. has granted permission for use of the article.
JPMA Requests Broader Support for Pipeline to Obtain Approval